Back
Legal

Brexit is not that frustrating

Allyson Colby offers her analysis of the highly anticipated decision over the European Medicines Agency’s office lease in Canary Wharf


Key points

  • Brexit will not frustrate a lease to the European Medicines Agency (EMA)
  • The EMA can lawfully retain and deal with its London premises, despite Brexit
  • The parties did not enter into the lease for a common purpose that will be thwarted by Brexit
  • Alienation provisions in the lease should be allowed to do their job

Many were saddened by the news that the European Medicines Agency (EMA) would leave London. Picture, however, the dismay of its landlord, who spent more than £40m to induce the EMA to sign a 25-year lease of offices in Canary Wharf at a rent of £13m per annum. The lease was signed in 2014 and had barely begun when the United Kingdom voted to leave the European Union.

Start your free trial today

Your trusted daily source of commercial real estate news and analysis. Register now for unlimited digital access throughout April.

Including:

  • Breaking news, interviews and market updates
  • Expert legal commentary, market trends and case law
  • In-depth reports and data-led analysis

Up next…